NURIX THERAP. DL-,001

Nurix Therapeutics' stock rose to a 52-week high of $26.40 and posted a one-year total return of 159% with a market capitalization of $2.72 billion; according to InvestingPro the stock is trading near its fair value. Analysts raised price targets after the Q2 report and the collaboration agreement with Roche (Mizuho, Truist, Baird, Morgan Stanley) and maintained positive ratings. InvestingPro predicts a return to profitability this year with an expected EPS of $3.80. » Más en de.investing.com

Nurix Therapeutics' stock closed at $25.22, reaching a 52-week high, supported by a year-to-date gain of around 140.5% and a six-month increase of about 55%. Analysts raised several price targets and maintained mostly positive ratings following the Q2 2026 earnings report and the collaboration agreement with Roche on Bexdeg. A fair-value analysis by InvestingPro currently rates the stock as slightly overvalued, placing it on the watchlist for significantly overvalued names. » Más en de.investing.com

Nurix has enrolled the first patient in the global, randomized phase-3 study DAYBreak CLL-306, which is evaluating bexobrutideg in patients with relapsed or refractory CLL/SLL after treatment with covalent BTK inhibitors. About 620 patients will be randomized 1:1 to receive either 600 mg bexobrutideg orally once daily or pirtobrutinib. Primary endpoints are objective response rate and progression-free survival, assessed by an independent review committee. The study is being conducted in collaboration with Roche and aims to demonstrate potential superiority of BTK degradation versus non-covalent inhibition and to support regulatory submissions worldwide. » Más en de.investing.com